Internationally Recognized Neuroendocrine Tumor Surgeon to Join Rocky Mountain Cancer Centers
DENVER, May 13, 2015 /PRNewswire/ -- Dr. Eric Liu, internationally recognized surgeon, specializing in neuroendocrine tumors (NET), will be joining Rocky Mountain Cancer Centers (RMCC) on June 1st. He is among a select group of specialists in the United States dedicated to the treatment of this complex and often misdiagnosed cancer, best known as the "cancer that Steve Jobs had." Dr. Liu completed a fellowship under Dr. Kjell Oberg in Sweden, considered the pioneer of neuroendocrine research, and was responsible for establishing the first clinical trial in the United States for the Gallium 68 PET/CT, an important tool in diagnosing patients with NET.
Dr. Liu comes to Rocky Mountain Cancer Centers from Vanderbilt University in Nashville, TN, where he established a Neuroendocrine Center. He also serves as the Chief Medical Advisor for Healing NET Foundation, a 501(c)(3) dedicated to providing education about neuroendocrine cancers to the medical community, and supporting the best possible care for neuroendocrine patients.
"We are excited about Dr. Liu joining Rocky Mountain Cancer Centers because of the opportunity it represents to elevate public awareness about neuroendocrine cancers and the advanced diagnostic and treatment options now available," says Dr. John Fleagle, president, Rocky Mountain Cancer Centers.
"Rocky Mountain Cancer Centers' commitment to delivering high-quality, patient-centered care is well known in the cancer community," says Dr. Liu. "We are committed to building a state-of-the-art neuroendocrine center where patients from all over the world can feel at home. I am excited to have the opportunity to collaborate with other highly skilled cancer and interventional radiology specialists."
Dr. Liu will be based out of Rocky Mountain Cancer Centers' Midtown location, centrally located near downtown Denver. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up a new Neuroendocrine Tumor Center in conjunction with HealthONE's Presbyterian/St. Luke's Medical Center. "Our Center will fill a much needed void in care for NET patients who often end up traveling the globe seeking a correct diagnosis and the latest treatment options," says Dr. Cohn.
HealthONE's Presbyterian/St. Luke's President and CEO, Maureen Tarrant says, "The multi-disciplinary team, under Dr. Liu's direction will deliver a high quality surgical care plan to our patients. It is our privilege to offer this advanced surgical program not only to our community but to the national and international communities."
About Rocky Mountain Cancer Centers
Rocky Mountain Cancer Centers is Colorado's largest and most comprehensive provider of cancer care with 58 physicians treating patients in 19 community-based locations across the state. We are united in healing with The US Oncology Network, one of the nation's largest networks of integrated community-based oncology practices dedicated to advancing high-quality, evidence-based patient care.
About HealthONE's Presbyterian/St. Luke's Medical Center
For 134 years, HealthONE's Presbyterian/St.Luke's Medical Center has been meeting the healthcare needs of patients and their families from across the Rocky Mountain and Great Plains regions, and from around the world. With over 80 specialties, 1,000 specialists and primary care physicians, and 1,800 employees, P/SL is the only tertiary/quaternary care hospital in a seven state region that offers one campus with leading comprehensive care, featuring Advanced Centers for Minimally Invasive Surgery, Cardiovascular Services, Cancer/BMT, Pediatrics, Maternal-Fetal Care, Orthopedics, Kidney Transplant, HBO, Wound Healing, Infectious Diseases and more. P/SL provides compassionate and innovative care. Licensed for 680 beds, P/SL is the largest hospital in Colorado.www.pslmc.com
SOURCE Rocky Mountain Cancer Centers
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article